Repurposing briefs from the LatentDx platform
Each post is a plain-language write-up of a virtual-screening hit — an approved drug that shows computational binding affinity against a disease target. Predictions require experimental validation.
Aripiprazole → Autism
Our AI drug repurposing platform, LatentRx, has identified a high-priority potential new application for an existing medication. The drug, aripiprazole, is predicted to be effective for core characteristics of Autism Spectrum Disorder (ASD) through a specific biological mechanism. Aripiprazole is an approved medication sometimes used to treat irritability associated with autism. However, our computational analysis suggests a deeper connection. The platform predicted that aripiprazole binds with very high affinity (-10.97 kcal/mol) to the serotonin 2A receptor, also known as HTR2A. This receptor is part of the brain's serotonin system, which plays a crucial role in regulating mood, cognition, and social behavior—functions often impacted in individuals with ASD. The strength of this predicted interaction suggests that targeting HTR2A could be a primary mechanism through which aripiprazole exerts a therapeutic effect. While the drug's interaction with HTR2A is known, our model elevates its importance in the context of autism's underlying neurobiology. This finding provides researchers with a specific, testable hypothesis that could reframe our understanding of how aripiprazole works in this population and potentially lead to more targeted clinical investigations. This is a computational prediction that requires experimental validation in a laboratory setting to confirm the binding interaction and its functional effects.
Valproate → Autism
Our AI drug discovery platform, LatentRx, has identified a promising connection between an existing medication and Autism Spectrum Disorder (ASD). A virtual screening run flagged Valproate, a drug traditionally used to treat epilepsy and bipolar disorder, as a strong candidate for repurposing. The platform’s analysis predicts that Valproate binds very effectively to a specific protein in the brain: the serotonin 2A receptor, or HTR2A. The predicted binding affinity of -10.64 kcal/mol indicates a strong and stable interaction. This is significant because the serotonin system plays a crucial role in regulating mood, social processing, and cognition, which can be challenging areas for individuals with ASD. While Valproate is a well-understood drug, this predicted interaction with HTR2A is a novel mechanism that is not part of its currently known effects. This finding provides a new, specific, and testable hypothesis for how Valproate could potentially address certain neurological aspects of ASD. It opens a new avenue of research, suggesting that a familiar drug might have a hidden ability to modulate a key system involved in this complex condition. It is important to emphasize that this is a computational prediction and not a clinical recommendation. The next step is to perform laboratory experiments to validate whether Valproate interacts with the HTR2A receptor as predicted.